Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results, Misses Expectations By $0.04 EPS

Oruka Therapeutics (NASDAQ:ORKA) posted its quarterly earnings results on Monday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04), FiscalAI reports.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock opened at $98.82 on Monday. Oruka Therapeutics has a 1 year low of $12.84 and a 1 year high of $100.34. The company has a market cap of $5.96 billion, a P/E ratio of -50.94 and a beta of -0.34. The stock has a 50-day moving average price of $82.59 and a 200 day moving average price of $60.25.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research report on Thursday, April 30th. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Barclays boosted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. Finally, UBS Group increased their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Insiders Place Their Bets

In other news, Director Carl Dambkowski sold 105,000 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total value of $6,191,850.00. Following the completion of the sale, the director directly owned 73,743 shares of the company’s stock, valued at $4,348,624.71. This represents a 58.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the sale, the senior vice president owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. This represents a 38.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 188,406 shares of company stock worth $12,019,683. Insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ORKA. Landscape Capital Management L.L.C. purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $226,000. BNP Paribas Financial Markets raised its stake in shares of Oruka Therapeutics by 105.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,747 shares of the company’s stock worth $111,000 after purchasing an additional 2,944 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Oruka Therapeutics by 287.6% during the 2nd quarter. Bank of America Corp DE now owns 18,849 shares of the company’s stock worth $211,000 after purchasing an additional 13,986 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at about $167,000. Finally, Invesco Ltd. acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at about $172,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.